--- title: "The international president of Eli Lilly stated that the company is studying the new fast-track revi" description: "The international president of Eli Lilly stated that the company is studying the new fast-track review process of the U.S. Food and Drug Administration, but it cannot assume that its new weight loss d" type: "news" locale: "en" url: "https://longbridge.com/en/news/257670240.md" published_at: "2025-09-17T07:25:20.000Z" --- # The international president of Eli Lilly stated that the company is studying the new fast-track revi > The international president of Eli Lilly stated that the company is studying the new fast-track review process of the U.S. Food and Drug Administration, but it cannot assume that its new weight loss drug will be approved in this manner The international president of Eli Lilly stated that the company is studying the new fast-track review process of the U.S. Food and Drug Administration, but it cannot assume that its new weight loss drug will be approved in this manner ### Related Stocks - [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 禮來公司（LLY）建立了價值 15 億美元的減肥藥庫存 | 禮來（LLY）已準備好 15 億美元的庫存，以迎接其新減肥藥 Orforglipron 預計在四月獲得 FDA 批准。該公司計劃在今夏推出該藥，並進行大規模的營銷活動，以與諾和諾德的 Wegovy 競爭。分析師對禮來的股票給予了一致的強烈買 | [Link](https://longbridge.com/en/news/276070062.md) | | 禮來公司 $LLY 的股票被 Assetmark Inc. 收購 | Assetmark Inc. 在第三季度將其在禮來的持股增加了 6.0%，目前持有 55,360 股，價值為 4224 萬美元。其他機構投資者也增持了股份，82.53% 的股票由對沖基金持有。禮來的股票開盤價為 1,040.12 美元，市值 | [Link](https://longbridge.com/en/news/275971336.md) | | “她每月花費超過 1000 美元在減肥藥上”：我的兒子在與他的女朋友相識後，財務狀況一團糟。責任在誰？ | 一位母親反思她兒子的財務困境，因為他與女友混合了財務，而女友是一個不理智的消費人。在他們分手後，他的信用評級受到了影響，這影響了他獲得貸款的能力。這位母親強調了在關係中設定財務界限的重要性，並建議雙方對財務決策共同承擔責任。專家建議未婚情侶 | [Link](https://longbridge.com/en/news/276446748.md) | | “她每月花費 1000 美元購買減肥藥”：我的兒子在與女友交往後財務狀況一團糟。責任在誰？ | 一位母親反思了她兒子的財務困境，因為他與女友混合了財務，而女友是一個揮霍無度的消費者。儘管他很聰明，但由於他們共同的財務決策，他的信用評級受到了影響。這位母親強調了在關係中設定個人和財務界限的重要性。文章討論了未婚情侶共同管理財務的日益趨勢 | [Link](https://longbridge.com/en/news/276515541.md) | | 禮來公司在克羅恩病治療領域取得了新的突破 | 禮來（Eli Lilly，股票代碼：LLY）宣佈其克羅恩病治療藥物 Omvoh 的第三階段重要結果，超過 90% 的患者實現了三年無類固醇緩解。VIVID-2 研究顯示，臨牀緩解率為 92.4%，無類固醇緩解率為 91.2%。Omvoh 還 | [Link](https://longbridge.com/en/news/276442344.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.